Transforming the Treatment

Of Kidney Disease

Kidney disease is a public health crisis

More than 850 million people worldwide suffer from some form of kidney disease. This includes those with chronic kidney disease (CKD), which is when the kidneys are damaged and progressively fail, and acute kidney injury (AKI), which is a rapid loss of kidney function over a short period of time.

37M

In the US alone, there are 37 million patients suffering from CKD vs. 17 million cancer patients

MORE THAN
20X

This is more than 20X the number of people with cancer (44 million) or HIV/AIDS (38 million) worldwide

2x

This is 2X the number of diabetes patients (422 million)

1 in 5

Adults suffer from AKI during a hospital stay

Walden Biosciences is a completely different type of biotech company
Our science is changing the treatment of kidney disease for patients
Join us for a professional experience like no other
Latest News
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
Walden Biosciences Promotes Curt Dewan, CFA to Chief Financial Officer
Walden Biosciences Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference